Dopamine D2 receptor occupancy by perospirone: A positron emission tomography study in patients with schizophrenia and healthy subjects

Psychopharmacology

Volumn 209, Issue 4, 2010, Pages 285-290

  Arakawa, Ryosuke ^a,b   Ito, Hiroshi ^a   Takano, Akihiro ^a   Okumura, Masaki ^a,b   Takahashi, Hidehiko ^a   Takano, Harumasa ^a   Okubo, Yoshiro ^b   Suhara, T ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Dopamine D2 receptor occupancy; Perospirone; Positron emission tomography; Schizophrenia; Time course

Indexed keywords

ANTIPARKINSON AGENT; BENZODIAZEPINE DERIVATIVE; DOPAMINE 2 RECEPTOR; ISOREMOXIPRIDE C 11; PEROSPIRONE; RACLOPRIDE C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; DOPAMINE RECEPTOR BLOCKING AGENT; ISOINDOLE DERIVATIVE; NEUROLEPTIC AGENT; RACLOPRIDE; THIAZOLE DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; SINGLE DRUG DOSE; BINDING COMPETITION; BLOOD; BRAIN; CASE CONTROL STUDY; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; SCINTISCANNING; TIME;

ADULT; ANTIPSYCHOTIC AGENTS; BINDING, COMPETITIVE; BRAIN; CASE-CONTROL STUDIES; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; ISOINDOLES; MAGNETIC RESONANCE IMAGING; MALE; POSITRON-EMISSION TOMOGRAPHY; RACLOPRIDE; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; THIAZOLES; TIME FACTORS;

EID: 77953283895     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-010-1783-1     Document Type: Article

References (27)

1. Arakawa R, Ito H, Takano A, Takahashi H, Morimoto T, Sassa T, Ohta K, Kato M, Okubo Y, Suliara T (2008) Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl) 197:229-235
2. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544
3. Gaebel W, Janner M, Frommann N, Pietzcker A, Kopeke W, Linden M, Muller P, Muller-Spahn F, Tegeler J (2002) First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophr Res 53:145-159 (Pubitemid 33139783)
4. Gefvert O, Bergstrom M, Langstrom B, Lundberg T, Lindstrom L, Yates R (1998) Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology (Berl) 135:119-126
5. Herz MI, Glazer WM, Mostert MA, Sheard MA, Szymanski HV, Hafez H, Mirza M, Vana J (1991) Intermittent vs maintenance medication in schizophrenia. Two-year results. Arch Gen Psychiatry 48:333-339
6. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, lida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533-1539
7. Ito H, Arakawa R, Takahashi H, Takáno H, Okumura M, Otsuka T, Ikoma Y, Shidahara M, Suhara T (2009) No regional difference in dopamine D2 receptor occupancy by the second-generation antipsychotic drug risperidone in humans: a positron emission tomography study. Int J Neuropsychopharmacol 12:667-675
8. Kapur S, Seeman P (2001) Does fast dissociation from the dopamine d2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 158:360-369
9. Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000a) Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514-520 (Pubitemid 30191189)
10. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P (2000b) A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 57:553-559
11. Kusumi I, Masui T, Koyama T (2008) Long-term perospirone treatment with a single dose at bedtime in schizophrenia: relevant to intermittent dopamine D2 receptor antagonism. Prog Neuropsychopharmacol Biol Psychiatry 32:520-522
12. Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4:153-158 (Pubitemid 27024284)
13. Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, Uppfeldt G (1993) Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 33:227-235
14. Onrust SV, McClellan K (2001) Perospirone. CNS Drugs 15:329-337, discussion 338
15. Pilowsky LS, Mulligan. RS, Acton PD, Ell PJ, Costa DC, Kerwin RW (1997) Limbic selectivity of clozapine. Lancet 350:490-491
16. Remington G, Seeman P, Shammi C, Mann S, Kapur S (2005) "Extended" antipsychotic dosing: rationale and pilot data. J Clin Psychopharmacol 25:611-613
17. Samaha AN, Reckless GE, Seeman P, Diwan M, Nobrega JN, Kapur S (2008) Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. Biol Psychiatry 64:145-152
18. Schooler NR, Keith SJ, Severe JB, Matthews SM, Bellack AS, Glick ID, Hargreaves WA, Kane JM, Ninan PT, Frances A, Jacobs M, Lieberman JA, Manee R, Simpson GM, Woerner MG (1997) Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. Arch Gen Psychiatry 54:453-463
19. Seeman P (2002) Atypical antipsychotics: mechanism of action. Can J Psychiatry 47:27-38
20. Sekine Y, Ouchi Y, Takei N, Yoshikawa E, Okada H, Minabe Y, Nakamura K, Suzuki K, Iwata Y, Tsuchiya KJ, Sugihara G, Mori N (2006) Perospirone is a new generation antipsychotic: evidence from a positron emission tomography study of serotonin 2 and D2 receptor occupancy in the living human brain. J Clin Psychopharmacol 26:531-533
21. Suhara T, Sudo Y, Okauchi T, Maeda J, Kawabe K, Suzuki K, Okubo Y, Nakashima Y, Ito H, Tanada S, Halldin C, Farde L (1999) Extrastriatal dopamine D2 receptor density and affinity in the human brain measured by 3D PET. Int J Neuropsychopharmacol 2:73-82
22. Takahashi Y, Kusumi I, Ishikane T, Koyama T (1998) In vivo occupation of dopamine Dl, D2 and serotonin2A receptors by novel antipsychotic drug, SM-9018 and its metabolite, in rat brain. J Neural Transm 105:181-191
23. Takano A, Suhara T, Ikoma Y, Yasuno F, Maeda J, Ichimiya T, Sudo Y, Inoue M, Okubo Y (2004) Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. Int J Neuropsychopharmacol 7:19-26 (Pubitemid 38523803)
24. Talvik M, Nordstrom AL, Nyberg S, Olsson H, Halldin C, Farde L (2001) No support for regional selectivity in clozapine-treated patients: a PET study with. [11.C]raclopride and [11C]FLB 457. Am J Psychiatry 158:926-930
25. Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S (2002) Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatiy 7:317-321 (Pubitemid 34280640)
26. Yasui-Furukori N, Inoue Y, Tateishi T (2003) Determination of a new atypical antipsychotic agent perospirone and its metabolite in human plasma by automated column-switching high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 789:239-245
27. Yasui-Furukori N, Furukori H, Nakagami T, Saito M, Inoue Y, Kaneko S, Tateishi T (2004) Steady-state pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response. Ther Drug Monit 26:361-365